Evidence map›Paper›PMID 37326399›Full record

ArticleActa medica academica2023

COVID-19 Seroprevalence in Children during Pandemic Waves in Sarajevo, a Single Center Experience.

Senka Mesihović-Dinarević, Mirela Lisičić-Konaković, Jasminka Prguda-Mujić, Anes Jogunčić

Abstract read
In one paragraph

Article in Acta medica academica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Senka Mesihović-DinarevićDepartment of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina.
Mirela Lisičić-KonakovićPediatrics Department, Ilidža Health Center, The Public Institution Health Centre of Sarajevo Canton, Sarajevo, Bosnia and Herzegovina. m.konakovic@gmail.com.
Jasminka Prguda-MujićEurofarm Molecular Diagnostics Laboratory, Eurofarm Centre, Sarajevo, Bosnia and Herzegovina.
Anes JogunčićDepartment of Epidemiology, Institute for Public Health of Sarajevo Canton, Sarajevo, Bosnia and Herzegovina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to present data on the prevalence of seropositive children tested in the laboratory of the Eurofarm polyclinic in Sarajevo, from September 2020 to May 2021. MATERIALS AND

methodsPeripheral blood samples were collected and anti-SARS-CoV-2 antibodies were detected using an electrochemiluminescence immunoassay.

resultsIn the total of 762 tested children, 187 were positive (24.5%), based on cut-off value. Of all the positive cases 42.8% were female while 57.2% were male. There were 10.1% of positive children in the first age group (0-5 years), 44.4% in the second group (6-13 years), and 45.5% in the third group (14-18 years). There was no statistically significant difference in seroprevalence between age groups and gender. The lowest seroprevalence (3.6%) was observed in October 2020 after the first pandemic wave, and the highest seroprevalence (60.3%) was observed in April 2021, corresponding to the third pandemic wave.

conclusionThe results of our study showed that the seroprevalence in children was low, especially during the first year of the pandemic. In the second year of the pandemic, there was an evident statistically significant increase in the number of seropositive children. Similar data have been shown in studies for adults.

Indexed as

COVID-19AdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornMalePandemicsSeroepidemiologic StudiesAntibodiesChildrenCOVID-19SARS-CoV-2Seroprevalence

Identifiers

PMID37326399
PMCPMC10316078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.